维布妥昔单抗治疗儿童复发或难治性霍奇金淋巴瘤和间变性大细胞淋巴瘤:一项多中心、开放标签、1/2期研究
这项多中心开放标签1/2期研究纳入36例7-18岁复发或难治性经典霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤患儿,评估维布妥昔单抗的安全性和疗效。最大耐受剂量未达到,推荐2期剂量为1.8 mg/kg。经典霍奇金淋巴瘤总体缓解率为47%(95%CI 21-73),系统性间变性大细胞淋巴瘤为53%(95%CI 28-77)。
要点
- 推荐2期剂量为1.8 mg/kg,每3周静脉输注一次,最多16个周期。
- 经典霍奇金淋巴瘤总体缓解率47%(95%CI 21-73),间变性大细胞淋巴瘤53%(95%CI 28-77)。
- 16例(44%)发生至少1次3级或更差治疗中出现的不良事件。
核心结论
- 维布妥昔单抗毒性可控,在儿童复发或难治性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤中与有临床意义的缓解相关,并可能使部分初始不适合干细胞移植的患者后续接受干细胞移植。
研究设计与样本
- 开放标签、剂量递增1/2期研究,在8个国家(法国、德国、意大利、墨西哥、荷兰、西班牙、英国和美国)的12个中心进行。
- 纳入7-18岁复发或难治性经典霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤患者,标准治疗不可用或不再有效。
- 2012年4月16日至2016年4月4日筛查41例患儿,入组36例,其中经典霍奇金淋巴瘤19例、系统性间变性大细胞淋巴瘤17例。
- 维布妥昔单抗1.4 mg/kg(1期)或1.8 mg/kg(1期和2期)静脉输注,每3周一次,最多16个周期;剂量递增采用3+3设计。
主要发现
- 最大耐受剂量未达到,推荐2期剂量为1.8 mg/kg。
- 经典霍奇金淋巴瘤总体缓解率为47%(95%CI 21-73),系统性间变性大细胞淋巴瘤为53%(95%CI 28-77)。
- 全部36例均发生治疗中出现的不良事件,16例(44%)发生至少1次3级或更差治疗中出现的不良事件。
- 最常见的治疗中出现的不良事件为发热(16/36,44%)和恶心(13/36,36%)。
- 最常见的3级或更差治疗中出现的不良事件为中性粒细胞减少(4例,11%)、γ-谷氨酰转肽酶升高(2例,6%)和发热(2例,6%)。
关键数值与推荐
- 推荐2期剂量为1.8 mg/kg,每3周静脉输注一次,最多16个周期。
- 12例(33%)发生短暂、严重程度有限的外周神经病变。
- 8例(22%)发生严重不良事件,其中3例(8%)为药物相关严重不良事件。
- 1例死于心脏骤停(巨大纵隔肿块疾病进展,与研究药物无关)。
- 儿童药代动力学特征与成人研究一致。
临床怎么用
- 作者认为维布妥昔单抗毒性可控,在儿童复发或难治性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤中与有临床意义的缓解相关。
- 作者认为维布妥昔单抗可能使部分初始不适合干细胞移植的患者后续接受干细胞移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite remarkable progress in the treatment of newly-diagnosed classical Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, treatment of relapsed or refractory disease remains challenging. The aims of this study were to assess the safety, tolerability, recommended phase 2 dose, and efficacy of brentuximab vedotin in paediatric patients with relapsed or refractory Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. METHODS: This open-label, dose-escalation phase 1/2 study was done at 12 centres across eight countries (France, Germany, Italy, Mexico, The Netherlands, Spain, UK, and USA). We recruited paediatric patients aged 7-18 years with relapsed or refractory classical Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma, for whom standard treatment was unavailable or no longer effective. Participants were allocated to receive brentuximab vedotin at 1·4 mg/kg (phase 1) or 1·8 mg/kg (phases 1 and 2) via intravenous infusion once every 3 weeks for up to 16 cycles. Dose escalation was done via a 3+3 design. Key exclusion criteria were stem-cell transplantation less than 3 months before administration of the first dose of study drug, presence of cytomegalovirus infection after allogeneic stem-cell transplantation, previous treatment with an anti-CD30 antibody, and concurrent immunosuppressive or systemic therapy for chronic graft-versus-host disease. Primary outcomes were safety profile in the safety-evaluable population and maximum tolerated dose, recommended phase 2 dose, pharmacokinetics (phase 1), and proportion of patients who achieved best overall response (phase 2; evaluated by an independent review facility) in the response-evaluable population. This trial is registered with ClinicalTrials.gov, number NCT01492088. FINDINGS: Between April 16, 2012, and April 4, 2016, we screened 41 paediatric patients and enrolled 36 (aged 7-18 years), of whom 19 had relapsed or refractory classical Hodgkin's lymphoma and 17 had relapsed or refractory systemic anaplastic large-cell lymphoma. At the data cutoff (Oct 12, 2016), all 36 patients had discontinued study drug treatment; the most common reason was progressive disease (15 patients). The maximum tolerated dose was not reached. The recommended phase 2 dose was 1·8 mg/kg. The proportion of patients who achieved overall response was 47% (95% CI 21-73) for classical Hodgkin's lymphoma and 53% (28-77) for systemic anaplastic large-cell lymphoma. All 36 patients had a treatment-emergent adverse event and 16 patients (44%) had at least one grade 3 or worse treatment-emergent adverse event. The most common treatment-emergent adverse events were pyrexia (16 [44%] of 36) and nausea (13 [36%]). The most common grade 3 or worse treatment-emergent adverse events were neutropenia (four [11%]), increased γ-glutamyl transpeptidase (two [6%]), and pyrexia (two [6%]). 12 (33%) patients had transient, limited-severity peripheral neuropathy. Eight patients (22%) had a serious adverse event; three (8%) had a drug-related serious adverse event. One patient died of cardiac arrest (disease progression of a large huge mediastinal mass, unrelated to the study drug). Paediatric pharmacokinetic profiles were consistent with those from studies of adult patients. INTERPRETATION: Brentuximab vedotin has manageable toxicity and is associated with clinically meaningful responses in paediatric patients with relapsed or refractory Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma, and could allow subsequent stem-cell transplantation in some patients who were initially ineligible for stem-cell transplantation. FUNDING: Millennium Pharmaceuticals Inc.
引用
- Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018. PMID: 30290902. doi:10.1016/S2352-3026(18)30153-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。